Compare CubeSmart (CUBE) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CubeSmart vs TransMedics Group Inc — how do they compare? CubeSmart trades at $37.56 (market cap $8.45B), while TransMedics Group Inc trades at $79.01 (market cap $2.81B). The key difference: CubeSmart is far larger — about 3× TransMedics Group Inc's market cap, and CubeSmart pays a 5.65% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CubeSmart for 89 Days and TransMedics Group Inc for 24 Days on average.
| CUBE | TMDX | |
|---|---|---|
Market Cap | $8.45B | $2.81B |
Volume | 2,879,532 | 962,415 |
Sector | Real Estate | Health |
52-Week High | $42.50 | $150.42 |
52-Week Low | $35.36 | $61.99 |
Typical Hold Time | 89 Days | 24 Days |
Enterprise Value | $11.97B | $3.21B |
Dividend Yield | 5.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CubeSmart (CUBE) trades at $37.23, down 1.4% on the day, amid a bearish technical signal from moving averages. The self-storage REIT reported mixed Q2 2026 results with an FFO miss but revenue beat, and same-store NOI declined 0.7%. Financials show strong gross margins of 67.83% and net income margin of 29.41%, though net income has trended down from $411M in 2023 to $334M in 2025. Analyst consensus is a Buy with a $44.00 price target, implying 18% upside, but technical indicators suggest near-term resistance at $38.
CUBE offers a 5.4% dividend yield with a payout scheduled for October 2026, supporting income-focused investors. Upside is driven by moderating supply and strengthening demand in the self-storage sector, but risks include high leverage with $2.99B long-term debt and macroeconomic sensitivity. Institutional activity is mixed, with new positions from Deutsche Bank and Barrow Hanley offset by selling from HSBC. The stock presents a value opportunity if operational improvements materialize, though debt levels and same-store performance warrant caution.
TransMedics Group (TMDX) trades at $81.07, up 0.98% on the day, but remains in a technical downtrend with a bearish moving average signal. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying but also multiple legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 analyst target but faces near-term headwinds from earnings misses and legal overhangs. Key risks include execution pressure from heavy investments and ongoing legal scrutiny, while the core organ transplant technology business maintains a growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
